A newly-discovered hereditary mutation is responsible for an increased production of erythropoietin (EPO) in the blood. This mutation causes a messenger RNA (mRNA) that is not normally involved in the formation of proteins to be reprogrammed so that it produces EPO, thus abnormally increasing the number of red blood cells.
With every infection or vaccination, memory cells form that the body uses to remember the pathogen. This has been known for decades – but the structure of this cellular immunologic memory has previously proven impossible to pin down. Researchers from the University of Basel and University Hospital Basel have now identified a microanatomical region in memory cells that enables them to work rapidly in the first few hours of an immune response, as they report in the journal Immunity.
In 2020, the European Space Agency (ESA) is sending a rover into space to examine the surface of Mars for signs of life. Its on-board equipment includes a high-resolution camera developed in Switzerland, and researchers from the University of Basel are currently testing the camera’s operation in an artificial Martian landscape.
Cellular energy metabolism also follows the rhythm of the circadian clock. A University of Basel study has now shown exactly how this works by revealing the relationship between the circadian rhythm and the mitochondrial network for the first time.
The University of Basel receives five of overall 39 new professorships awarded by the Swiss National Science Foundation (SNSF) this year.
The protein complex mTORC2 controls cellular lipid and carbohydrate metabolism. Researchers from the Biozentrum of the University of Basel and the ETH Zurich have now succeeded in deciphering the 3D structure of this important protein complex. The results have recently been published in “eLife”.
How do fish end up in isolated bodies of water when they can’t swim there themselves? For centuries, researchers have assumed that water birds transfer fish eggs into these waters – however, a systematic literary review by researchers at the University of Basel has shown that there is no evidence of this to date.
T3 Pharmaceuticals AG – a startup from the University of Basel – genetically modifies bacteria and wants to use this to develop new cancer therapies. The soon to be nine-strong team has already won prizes with its technology and completed a first round of financing.
Prof. Marek Basler from the Biozentrum at the University of Basel and Prof. Paola Picotti from the ETH Zurich have been selected to receive the Friedrich Miescher Award 2018. This prize is Switzerland's highest distinction for young scientists working in the field of biochemistry.